Published in Exp Hematol on October 20, 2011
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev (2003) 9.76
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 5.92
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell (1998) 4.77
Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem (1999) 4.56
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (1997) 4.29
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A (2005) 2.94
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood (1997) 2.75
Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol (2003) 2.45
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood (2010) 2.16
5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther (1991) 2.14
Hematopoietic cytokine receptor signaling. Oncogene (2007) 2.13
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia (2006) 1.90
N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem (2000) 1.80
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood (2010) 1.64
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia (2006) 1.40
Cleavage of Bax enhances its cell death function. Exp Cell Res (2000) 1.36
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer (2005) 1.34
Caspase cleavage of BimEL triggers a positive feedback amplification of apoptotic signaling. Proc Natl Acad Sci U S A (2004) 1.33
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem (2005) 1.32
Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem (2006) 1.31
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood (2010) 1.21
Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene (2005) 1.15
Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood (2000) 1.07
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci (1995) 1.07
Role of multiple cellular proteases in the execution of programmed cell death. FEBS Lett (1995) 1.06
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett (2009) 1.04
Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood (1999) 1.03
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol Cancer Ther (2008) 1.00
Receptors for interleukin-3 (IL-3) and growth hormone mediate an IL-6-type transcriptional induction in the presence of JAK2 or STAT3. Blood (1995) 0.97
Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res (1998) 0.91
The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol (2007) 0.89
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling. J Cell Mol Med (2009) 0.88
The cell cycle: accelerators, brakes, and checkpoints. Neurosurgery (2004) 0.88
The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. J Biol Chem (2010) 0.88
Growth hormone signalling and apoptosis in neonatal rat cardiomyocytes. Mol Cell Biochem (2001) 0.87
Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. J Biol Chem (2010) 0.87
Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. BMC Cancer (2011) 0.84
The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. Curr Med Chem (2010) 0.81
Sertaconazole: pharmacology of a gynecological antifungal agent. Int J Gynaecol Obstet (2000) 0.76
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med (2013) 2.26
Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. J Clin Invest (2015) 1.89
Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem Biophys (2004) 1.87
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59
SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. Cancer (2009) 1.59
Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One (2009) 1.57
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest (2015) 1.55
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood (2006) 1.50
PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci U S A (2004) 1.42
SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol (2009) 1.39
Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol (2009) 1.37
Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res (2013) 1.35
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol (2010) 1.34
MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27. J Biol Chem (2006) 1.33
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem (2005) 1.32
Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem (2002) 1.30
Trifecta nerve complex: potential anatomical basis for microsurgical denervation of the spermatic cord for chronic orchialgia. J Urol (2013) 1.28
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood (2003) 1.24
SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol (2009) 1.23
Impact of lipophilic efficiency on compound quality. J Med Chem (2012) 1.20
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem (2009) 1.11
Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol (2010) 1.10
Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Histopathology (2010) 1.10
Primary renal carcinoid tumors: clinicopathologic features of 9 cases with emphasis on novel immunohistochemical findings. Hum Pathol (2011) 1.09
Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem (2008) 1.07
Web-based synoptic reporting for cancer checklists. J Pathol Inform (2011) 1.07
RNA-binding protein LIN28 is a marker for testicular germ cell tumors. Hum Pathol (2011) 1.07
Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol (2003) 1.05
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett (2009) 1.04
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS One (2013) 1.03
RNA-binding protein LIN28 is a sensitive marker of ovarian primitive germ cell tumours. Histopathology (2011) 1.01
RNA-binding protein LIN28 is a marker for primary extragonadal germ cell tumors: an immunohistochemical study of 131 cases. Mod Pathol (2010) 1.01
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol Cancer Ther (2008) 1.00
Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol (2009) 1.00
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer Res (2013) 0.99
Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors. J Med Chem (2005) 0.99
A bony fish immunological receptor of the NITR multigene family mediates allogeneic recognition. Immunity (2008) 0.98
Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem (2004) 0.98
Dynamical concurrent schedules. J Exp Anal Behav (2003) 0.97
Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation. J Cell Biochem (2011) 0.96
Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J Biol Chem (2006) 0.95
Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening. J Med Chem (2009) 0.95
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol (2007) 0.94
The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry (2010) 0.94
Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med (2005) 0.94
Locally destructive skull base lesion: IgG4-related sclerosing disease. Allergy Rhinol (Providence) (2012) 0.94
SPAP2, an Ig family receptor containing both ITIMs and ITAMs. Biochem Biophys Res Commun (2002) 0.93
ANG II-induced cell proliferation is dually mediated by c-Src/Yes/Fyn-regulated ERK1/2 activation in the cytoplasm and PKCzeta-controlled ERK1/2 activity within the nucleus. Am J Physiol Cell Physiol (2006) 0.93
Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine. J Biol Chem (2003) 0.93
A neural network based classification scheme for cytotoxicity predictions:Validation on 30,000 compounds. Bioorg Med Chem Lett (2005) 0.92
Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. J Chem Inf Model (2010) 0.92
Rituximab-induced hypersensitivity pneumonitis. Respiration (2008) 0.91
The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cell Signal (2006) 0.91
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol (2014) 0.88
Application of the BD ACTOne technology for the high-throughput screening of Gs-coupled receptor antagonists. J Biomol Screen (2007) 0.88
The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. J Biol Chem (2010) 0.88
Homology modelling and binding site mapping of the human histamine H1 receptor. Eur J Med Chem (2004) 0.88
A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis. Mol Endocrinol (2004) 0.87
Jak2 tyrosine kinase prevents angiotensin II-mediated inositol 1,4,5 trisphosphate receptor degradation. Vascul Pharmacol (2005) 0.87
Identification of tyrosine 972 as a novel site of Jak2 tyrosine kinase phosphorylation and its role in Jak2 activation. Biochemistry (2008) 0.87
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol (2012) 0.87
Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. J Biol Chem (2010) 0.87
Vascular smooth muscle Jak2 mediates angiotensin II-induced hypertension via increased levels of reactive oxygen species. Cardiovasc Res (2011) 0.87
IgG4 Inflammatory Pseudotumor of the Kidney. Case Rep Urol (2012) 0.86
Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr Oncol Rep (2009) 0.86
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark (2007) 0.86
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia (2011) 0.86
Research resource: whole transcriptome RNA sequencing detects multiple 1α,25-dihydroxyvitamin D(3)-sensitive metabolic pathways in developing zebrafish. Mol Endocrinol (2012) 0.86
Enthalpic efficiency of ligand binding. J Chem Inf Model (2010) 0.86
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol (2012) 0.85
Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr Opin Drug Discov Devel (2009) 0.85
Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists. Bioorg Med Chem Lett (2009) 0.85
Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains. J Biol Chem (2003) 0.85
Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs. Bioorg Med Chem Lett (2010) 0.85
Histamine H4 receptor ligands and their potential therapeutic applications. Expert Opin Ther Pat (2009) 0.84
Expression of UTF1 in primary and metastatic testicular germ cell tumors. Am J Clin Pathol (2010) 0.84
Xp11.2 translocation renal carcinoma with placental metastasis: a case report. Int J Surg Pathol (2009) 0.84
Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. Eur J Med Chem (2007) 0.83
Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem (2013) 0.83
Jak2 tyrosine kinase residues glutamic acid 1024 and arginine 1113 form a hydrogen bond interaction that is essential for Jak-STAT signal transduction. Mol Cell Biochem (2004) 0.83
Activation mechanism of the human histamine H4 receptor--an explicit membrane molecular dynamics simulation study. J Chem Inf Model (2008) 0.83